The drospirenone progestin-only pill (POP) is an estrogen-free daily oral contraceptive that received regulatory approval in both the US and Europe in 2019 and is marketed in the US as Slynd. The drospirenone POP has yet to be written about on the CTI Exchange and we would like to take this opportunity to highlight this important method available in the mix now. This newer option is unique in that it has a more desirable bleeding profile, causing less breakthrough bleeding in users. It also has more flexible dosing, with a 24-hour missed pill window.
Recent research published in Contraception and The European Journal of Contraception & Reproductive Healthcare has reviewed the literature and clinical trials data for this newer method and includes the following:
Kommentarer